Physician profile
Michael W Baumann
NPI 1417953498
$2,540.82
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $293 · 2021: $440 · 2022: $443 · 2023: $630 · 2024: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $840.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $448.10 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $361.25 | 2019-2021 | |
| Alcon Vision LLC | $238.57 | 2022-2024 | Rocklatan, Clareon, Acrysof Iq Panoptix Uv Iol |
| Glaukos Corporation | $232.54 | 2023-2024 | Photrexa Cross-Linking Kit, Kxl System (Not Refurbished), Ce-Marked Kxla System |
| Johnson & Johnson Vision Care, INC. | $181.30 | 2022-2023 | Acuvue |
| Kala Pharmaceuticals, INC. | $158.33 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $151.09 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $145.71 | 2019-2021 | |
| Coopervision INC. | $105.61 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $94.40 | 2022-2024 | Vyzulta, Miebo |
| Mallinckrodt Hospital Products INC. | $79.20 | 2021-2022 | |
| Allergan, INC. | $64.62 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $57.49 | 2023-2024 | Syfovre |
| Rayner Intraocular Lenses Limited | $46.95 | 2023 | Rayone Spheric, Omidria, Rayone Emv |
| Biotissue Holdings INC. | $32.24 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27.08 | 2024 | |
| Omeros Corporation | $26.64 | 2019 | |
| Dompe US, INC. | $23.19 | 2019 | |
| Optos, INC. | $22.42 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $15.96 | 2024 | Xdemvy |
| Amgen INC. | $15.18 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $12.95 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Baumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.